Targeted Therapies and Developing Precision Medicine in Gastric Cancer.
Rille PihlakCaroline FongNaureen StarlingPublished in: Cancers (2023)
Gastric cancer is an aggressive disease with survival remaining poor in the advanced setting. More than a decade after the first targeted treatment was approved, still only HER2, MSI and PDL-1 status have reached everyday practice in terms of guiding treatment options for these patients. However, various new targets and novel treatments have recently been investigated and have shown promise in improving survival outcomes. In this review, we will summarise previous and currently ongoing studies on predictive biomarkers, possible new targeted treatments, potential reasons for conflicting trial results and hope for the future of precision medicine in gastric cancer.
Keyphrases
- end stage renal disease
- ejection fraction
- newly diagnosed
- cancer therapy
- primary care
- healthcare
- clinical trial
- peritoneal dialysis
- study protocol
- machine learning
- phase iii
- big data
- combination therapy
- patient reported outcomes
- climate change
- mass spectrometry
- quality improvement
- open label
- patient reported
- free survival
- human health